FH535 is a Wnt/-catenin signaling inhibitor and also a dual PPAR and PPAR antagonist.FH535 antagonizes -Catenin/TcfCmediated transcription, and inhibits recruitment of the coactivators GRIP1 and -catenin to PPAR and PPAR. FH535 shows selective anti-proliferation effect on some cancer cells expressing high or active Wnt/-catenin pathway.  FH535 increases cigarette smoke condensate cytotoxicity, and causes changes in -catenin and EGR-1 signaling.  FH535 has potential therapeutic value in treatment of liver cancer by targeting liver cancer stem cells and hepatocellular carcinoma cell lines.
For research use only. We do not sell to patients.